Drugs that block enzymes called tyrosine kinases are among the most effective targeted therapies for cancer. However, they ...

A recent study published in the journal Frontiers in Endocrinology investigated the role of the short-chain dehydrogenase/reductase 42E member 1 (SDR42E1) enzyme in regulating sterol metabolism and ...

A drug long used to fight cancer may soon take on a very different role. Researchers at the University of Illinois Chicago ...

The researchers used lipid nanoparticles (LNPs) to deliver cyclic GMP-AMP (cGAMP) synthase (cGAS) mRNA to cancer cells. This results in production of the endogenous stimulator of interferon genes ...

An octopus-shaped nanomachine hijacks tumor ATP leakage to power a self-amplifying cycle of membrane damage, drug delivery, and metabolic collapse in cancer cells.

A comprehensive study of clinical and molecular features in patients with metastatic colorectal cancer with and without liver mets. This is an ASCO Meeting Abstract from the 2025 ASCO Gastrointestinal ...

The meeting will focus on the potential to initiate a single-arm pivotal study evaluating pelareorep in combination with a checkpoint inhibitor in patients being treated with second-line and later ...

As of spring 2026, a cancer drug that has spent years in clinical development as a Wnt/beta-catenin pathway blocker has been ...

The FDA has granted Orphan Drug Designation to tovecimig (CTX-009) for the treatment of patients with biliary tract cancer ...

A local nonprofit supporting those impacted by cancer is being recognized while also expanding its reach in the community.